Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
NCT05400265
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Adult Solid Tumor
Interventions
DRUG:
HLX26
DRUG:
HLX10
Sponsor
Shanghai Henlius Biotech